FibroBiologics Granted Extension by Nasdaq to Regain Compliance

HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it received a favorable determination from a Nasdaq Hearings Panel granting an extension to regain compliance for the continued listing of the Company’s common stock on The Nasdaq Capital Market (“Nasdaq”).

This provides FibroBiologics with a clear path to maintaining its listing on Nasdaq, subject to the Company satisfying the following conditions: meeting the equity standard of $2.5 million required under Nasdaq Listing Rule 5550(b)(1), as an alternative to the $35 million minimum Market Value of Listed Securities as set forth in Listing Rule 5550(b)(2), on or before February 27, 2026; meeting the minimum bid price requirement of $1.00 per share set forth under Nasdaq Listing Rule 5550(a)(2) on or before April 13, 2026; and compliance with all applicable criteria for continued listing on Nasdaq on or before April 13, 2026.

This determination has no immediate effect on the listing or trading of the Company's shares of common stock, which will continue to trade on Nasdaq under the symbol “FBLG.”

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.